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Abstract: Background: This study aimed to determine human papillomavirus (HPV) vaccine uptake
and willingness to receive HPV vaccination among female college students, in China, and its associated
factors. Methods: An online cross-sectional survey of female college students across the eastern,
central, and western regions of China was undertaken between April and September 2019. Partial
least squares structural equation modeling (PLS-SEM) was used to examine factors associated with
the HPV vaccine uptake and willingness to receive the HPV vaccine. Results: Among the total
4220 students who participated in this study, 11.0% reported having been vaccinated against HPV.
There are direct effects of indicators of higher socioeconomic status, older age (β = 0.084 and p = 0.006),
and geographical region (residing in Eastern China, β = 0.033, and p = 0.024) on HPV vaccine uptake.
Higher knowledge (β = 0.062 and p < 0.000) and perceived susceptibility (β = 0.043 and p = 0.002)
were also predictors of HPV vaccine uptake. Of those who had not received the HPV vaccine, 53.5%
expressed a willingness to do so. Likewise, social economic status indicators were associated with
the willingness to receive the HPV vaccine. Total knowledge score (β = 0.138 and p < 0.001), both
perceived susceptibility (β = 0.092 and p < 0.001) and perceived benefit (β = 0.088 and p < 0.001),
and sexual experience (β = 0.041 and p = 0.007) had a positive and significant direct effect on the
willingness to receive the HPV vaccine, while perceived barriers (β = −0.071 and p < 0.001) had a
negative effect on the willingness to receive the HPV vaccine. Conclusions: Geographical region and
socioeconomic disparities in the HPV vaccination uptake rate and willingness to receive the HPV
vaccine provide valuable information for public health planning that aims to improve vaccination
rates in underserved areas in China. The influence of knowledge and perceptions of HPV vaccination
suggests the importance of communication for HPV immunization.
Keywords: HPV vaccination uptake; willingness to receive; female college student; China
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1. Introduction
Cervical cancer is the most common cancer of the female genital system, in China. It ranks as
the eighth most frequent cancer among women in China and is the second most prevalent cancer in
women aged between 15 and 44 years [1,2]. The National Central Cancer Registry of China reported an
estimated 4.29 million new incident cases (12,000 per day) and 2.81 million deaths (7500 per day) from
cervical cancer, in China, in 2015. This corresponds to an age-standardized incidence rate of 201.1 cases
per 100,000 and an age-standardized mortality rate of 126.9 deaths per 100,000 [3]. Recently, increasing
evidence has shown a significant rise in cervical cancer incidence among Chinese women aged below
35 years. Nearly a third of new cases are now found in women aged 35 and younger [4]. Although
the cervical cytology test has been considered an effective method to prevent cancer, and although
China has provided free cervical screenings in some rural areas for women aged 35 to 59 since 2009 [5],
evidence has shown that the uptake of the cervical cytology test rates remains alarmingly low among
women in China [6,7].
The introduction of the HPV vaccine in many countries has resulted in major decreases in the
specific human papillomavirus (HPV) infection rates. More than 10 years after the licensure of
the first HPV vaccines, 99 countries and territories worldwide have introduced HPV vaccination
programs [8]. A recently published systematic review and meta-analysis that included data from
60 million individuals and up to eight years of post-vaccination follow-up showed compelling
evidence of the substantial impact of HPV vaccination programs on HPV infections and the incidence
of associated diseases [9]. This encouraging finding suggests promising future prospects of HPV
vaccination reducing cervical cancer incidence and mortality. It is also anticipated that the HPV
vaccine should benefit China, especially as the country is facing challenges regarding cervical screening.
Most importantly, recent evidence from the first HPV vaccine trial in China showed that, among
Chinese women, the quadrivalent human papillomavirus (4vHPV) vaccine demonstrated robust
and sustained efficacy against HPV6/11/16/18-related persistent infections and high-grade cervical
disease for up to 6.5 years of follow-up [10]. The vaccine was also well tolerated with no evidence of
vaccine-related serious adverse events in the Chinese population [10]. A decade after the United States
Food and Drug Administration licensure in 2006, the first HPV vaccine was approved in China in 2016.
The GlaxoSmithKline’s bivalent vaccine, Cervarix®(GSK, Rixensart, Belgium), and Merck’s 4vHPV
vaccine, Gardasil®(Merck & Co., Inc, New Jersay, USA), were approved for use among women in
China, by the China Food and Drug Administration, in July 2016 and April 2017, respectively.
Several studies have examined willingness and intention to receive HPV vaccines among Chinese
females prior to the availability of the HPV vaccine in the Chinese market [11,12]. Now that the HPV
vaccine is available in the Chinese market, it is vitally important to provide sound evidence regarding
the actual HPV vaccine uptake rate, particularly among young adult women. There are several reasons
for this. First, young adult women are at the age at which it is best to receive the HPV vaccine because
they had no access to the HPV vaccine when they were adolescents. Secondly, owing to the high
prevalence of HPV infection [13,14], the high infection rate among young Chinese females [15] as
compared with older adults, and a variety of biological and behavioral reasons [14], sexually active
young female adults are at a particularly higher risk of acquiring sexually transmitted infections (STIs).
It is well established that college-aged students represent an important catch-up population of young
adult women for HPV vaccination. The college environment presents new opportunities for exposure
to STIs. In China, and indeed across the globe, evidence is mounting that STIs are on the rise among
college students and that college students are experiencing a high STI burden [16–18]. In addition, the
prevalence of HPV infection among Chinese women peaks between the ages of 20 and 24 [13], when
most are in their college or undergraduate years.
Currently, three years after the introduction of the HPV vaccine in China, information about
vaccine uptake and its acceptance among young adult Chinese women, particularly those at college or
university, is scarce. However, to the best of our knowledge, no study has reported real HPV vaccine
uptake among young women in China since it became available in the Chinese market. Information
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about HPV vaccination rates is crucial to enable the Chinese government to plan or carry out effective
strategies necessary to optimize uptake of the HPV vaccine.
The purpose of this study was to explore the uptake of HPV vaccination among young adult college
women in China and its associated factors. The second objective was to identify factors associated
with the willingness to receive the HPV vaccine among the unvaccinated female college students.
2. Materials and Methods
2.1. Study Participants and Survey Design
Using a cross-sectional design and convenience sampling method, young female college
students were recruited from a total of 136 universities throughout eastern (78 universities), western
(31 universities), and central (27 universities) regions of China. Participating universities were those that
responded positively to an invitation to assist with data collection. A survey was conducted between
April and September 2019. The inclusion criteria were all female students from the participating
universities. The survey was administered online. The link to the survey questions was sent to
administrators and lecturers from all invited universities for dissemination to registered female
students. In an attempt to achieve comprehensive recipient coverage, the link to the survey was also
sent to students’ social media groups or forums. Students who had received the survey link were also
encouraged to forward the link to their peers.
2.2. Instruments
The questionnaire consisted of sections that assessed demographic characteristics, risk behaviors,
knowledge, and health beliefs related to HPV infection and vaccination, HPV vaccine uptake, and
willingness to receive the HPV vaccine.
2.2.1. Demographics and Sexual Risk Profile
Personal details including age, ethnicity, study program, and year of study were collected.
The participants were asked to indicate whether they had partaken in any sexual activity, including
vaginal, oral, and anal sex. The participants who had done so were asked about safe sex practice
and their number of sexual partners. Safe sex was defined as sexual intercourse with the use of a
male condom.
2.2.2. Knowledge of HPV and HPV Vaccination
The participants’ knowledge was assessed using a series of questions regarding HPV infection,
the relationship of HPV infection with the development of cervical cancer and genital warts, and HPV
vaccination (20 item scale). The response options were “true”, “false”, or “don’t know”. A correct
response was given a score of 1 and an incorrect or “don’t know” response was scored 0. The possible
total knowledge score ranged from 0 to 20, with higher scores representing higher levels of knowledge.
2.2.3. Beliefs Surrounding HPV and HPV Vaccination
Health belief model (HBM) derived items were used to measure the participants’ beliefs about
HPV vaccination [19–21]. The questions probed perceived susceptibility to HPV (three items), perceived
severity of HPV infection (three items), perceived benefits of HPV vaccine (three items), and perceived
barriers to getting a vaccination against HPV (two items). The response option was “agree” or “disagree”.
2.2.4. Practice and Willingness to Receive HPV Vaccination
The participants were asked to indicate their HPV vaccination status. Those who had not received
the HPV vaccination were asked about their willingness to receive the HPV vaccine in the near future.
The response option was “yes” or “no”.
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The items in the questionnaire were content validated by several panel experts to ensure the
relevance and clarity of the questions. After minor amendments, the questionnaire was pilot tested on
randomly sampled students who were not included in the main study.
2.3. Ethical Considerations
This study was approved by the Medical School of Ningbo University Review Board, China
(reference number 20190506). The students were informed that their participation was voluntary, and
consent was implied on completion of the questionnaire. All responses were collected and analyzed
without identifiers.
2.4. Statistical Analysis
All statistical analyses were performed using the Statistical Package for the Social Sciences, version
20.0 (IBM Corp., Armonk, NY, USA). A p-value of less than 0.05 was considered statistically significant.
The reliability of knowledge items was evaluated by assessing the internal consistency of the items
representing the knowledge score. The 20 knowledge items in the study sample had a reliability
(Kuder–Richardson 20) of 0.931. Partial least squares structural equation modeling (PLS-SEM) was
used to quantify the contributing factors of HPV vaccine uptake and willingness to receive the HPV
vaccination. All variables showing statistically significant associations with HPV vaccine uptake
and willingness to receive the HPV vaccination in the univariate analyses were included in the
PLS-SEM. A bootstrapping approach was used to evaluate the significance of associations in the
proposed model. Bootstrapping includes the random resampling of the original dataset to generate
new samples of the same size as the original dataset. This technique not only assesses the reliability of
the dataset but also the statistical significance of the coefficients and the error of the estimated path
coefficients [22]. All PLS-SEM analyses were performed using SmartPLS 3.2.8 software (SmartPLS
GmbH, Bönningstedt, Germany).
3. Results
3.1. Characteristics of Participants
A total of 136 universities from eastern (n = 78), central (n = 27), and western (n = 31) regions
of China responded to the invitation to assist in recruiting participants for this survey. A total of
4220 completed responses were received between April and September 2019. The majority of the
responses were from western China (40.8%), followed by eastern (38.4%), and central China (20.8%).
A summary of the characteristics of the respondents is provided in the first column of Table 1.
Table 1. Demographic characteristics and univariate analyses of factors associated with HPV vaccine
uptake (N = 4220).
Univariate Analysis
HPV Vaccine Uptake
Overall Yes (N = 463) No (N = 3757) p-Value
Demographic Characteristics
Age group (years)
16–18 595 (14.1) 56 (9.4) 539 (90.6)
19–22 3056 (72.4) 292 (9.6) 2764 (90.4) p < 0.001
23 and above 569 (13.5) 115 (20.2) 454 (79.8)
Ethnicity
Han 3743 (88.7) 414 (11.1) 3329 (88.9) 0.641
Others 477 (11.3) 49 (10.3) 428 (89.7)




Overall Yes (N = 463) No (N = 3757) p-Value
Birthplace
Village 2753 (65.2) 265 (9.6) 2488 (90.4)
Town 757 (17.9) 78 (10.3) 679 (10.3) p < 0.001
City 710 (16.8) 120 (16.9) 590 (16.9)
Location
East China 1622 (38.4) 222 (13.7) 1400 (86.3)
West China 1721 (40.8) 148 (8.6) 1573 (91.4) p < 0.001
Central China 877 (20.8) 93 (10.6) 784 (89.4)
Type of university †
Type A 2292 (54.3) 268 (11.7) 2024 (88.3)
Type B 1272 (30.1) 130 (10.2) 1142 (89.8) 0.405
Type C 315 (7.5) 33 (10.5) 282 (89.5)
Type D 341 (8.1) 32 (9.4) 309 (90.6)
Year of study
First-year 1926 (45.6) 161 (8.4) 1765 (91.6)
Second-year 852 (20.2) 78 (9.2) 774 (90.8)
Third-year 611 (14.5) 66 (10.8) 545 (89.2) p < 0.001
Fourth-year 429 (10.2) 59 (13.8) 370 (86.2)
Fifth-year and postgraduate 402 (9.5) 99 (24.6) 303 (75.4)
Study program
Medical 2954 (70.0) 322 (10.9) 2632 (89.1) 0.830
Non-medical 1266 (30.0) 141 (11.1) 1125 (88.9)
Maternal educational level
Elementary school and below 1439 (34.1) 146 (10.1) 1239 (89.9)
Junior high school 1504 (35.6) 148 (9.8) 1356 (90.2) 0.019
High school or secondary school 869 (20.6) 112 (12.9) 757 (87.1)
University and above 408 (9.7) 57 (14.0) 351 (86.0)
Paternal educational level
Elementary school and below 836 (19.8) 93 (11.1) 743 (88.9)
Junior high school 1740 (41.2) 175 (10.1) 1565 (89.9) 0.001
High school or secondary school 1111 (26.3) 109 (9.8) 1002 (90.2)
University and above 533 (12.6) 86 (16.1) 447 (83.9)
Monthly disposable fund (RMB)
<1000 1217 (28.8) 109 (9.0) 1108 (91.0)
1000–1999 2326 (55.1) 230 (9.9) 2096 (90.1) p < 0.001
2000 and above 677 (16.0) 124 (18.3) 553 (81.7)
Perceived family economic status
Rich/Intermediate 2490 (59.0) 297 (11.9) 2193 (88.1) 0.019
Poor 1730 (41.0) 166 (9.6) 1564 (90.4)
Sexual risk profile
Ever had sexual experience
Yes 752 (17.8) 110 (14.6) 642 (85.4) 0.001
No 3468 (82.2) 353 (10.2) 3115 (89.8)
Number of sexual partner (n = 752)
1 517 (68.8) 74 (14.3) 443 (85.7) 0.739
>1 235 (31.3) 36 (15.3) 199 (84.7)




Overall Yes (N = 463) No (N = 3757) p-Value
Condom use (n = 752)
Never 31 (4.1) 6 (19.4) 25 (80.6)
Rarely 52 (6.9) 5 (9.6) 47 (90.4) 0.604
Sometimes 117 (15.6) 19 (16.2) 98 (83.8)
Always 552 (73.4) 80 (14.5) 472 (85.5)
History of being diagnosed with sexually transmitted
infection (n = 752)
Yes 69 (9.2) 12 (17.4) 57 (82.6) 0.477
No 683 (90.8) 98 (14.3) 585 (85.7)
Knowledge
Total Knowledge Score
Score 0–12 2021 (48.1) 167 (8.2) 1861 (91.8) p < 0.001
Score 13–20 2192 (51.9) 296 (13.5) 1896 (86.5)
Attitudes
Perceived susceptibility
Women in general have a high risk of contracting HPV
in their lifetime
Yes 3184 (75.5) 383 (12.0) 2801 (88.0) p < 0.001
No 1036 (24.5) 80 (7.7) 956 (92.3)
Women in general have a high risk of having genital
warts in their lifetime
Yes 2338 (55.4) 264 (11.3) 2074 (88.7) 0.488
No 1882 (44.6) 199 (10.6) 1683 (89.4)
Women in general have a high risk of having
cervical/vulvar cancer in their lifetime
Yes 3013 (71.4) 352 (11.7) 2661 (88.3) 0.019
No 1207 (28.6) 111 (9.2) 1096 (90.8)
Perceived severity
Harms of HPV infection for women are severe
Yes 3713 (88.0) 388 (10.4) 3325 (89.6) 0.005
No 507 (12.0) 75 (14.8) 432 (85.2)
Harms of genital warts for women are severe
Yes 3620 (85.8) 396 (10.9) 3224 (89.1) 0.888
No 600 (14.2) 67 (11.2) 533 (88.8)
Harms of cervical/vulvar cancer for women are severe
Yes 3925 (93.0) 436 (11.1) 3489 (88.9) 0.335
No 295 (7.0) 27 (9.2) 268 (90.8)
Perceived benefit
HPV vaccines are highly effective in preventing me from
HPV infection
Yes 3751 (88.9) 424 (11.3) 3327 (88.7) 0.050
No 469 (11.1) 39 (8.3) 430 (91.7)
HPV vaccines are highly effective in preventing me from
genital warts
Yes 3138 (74.4) 349 (11.1) 2789 (88.9) 0.612
No 1082 (25.6) 114 (10.5) 968 (89.5)
HPV vaccines are highly effective in preventing me from
cervical/vulvar cancer
Yes 3525 (83.5) 403 (11.4) 3122 (88.6) 0.033
No 695 (16.5) 60 (8.6) 635 (91.4)




Overall Yes (N = 463) No (N = 3757) p-Value
Perceived barriers
High cost of HPV vaccination
Yes 451 (10.7) 57 (12.6) 394 (87.4) 0.232
No 3769 (89.3) 406 (10.8) 3363 (89.2)
Fear of severe side effects
Yes 1091 (25.9) 104 (9.5) 987 (90.5) 0.081
No 3129 (74.1) 359 (11.5) 2770 (88.5)
† Types of University: Type A, National key universities and provincial key colleges; Type B, general undergraduate
universities (national enrollment); Type C, local undergraduate universities (provincial enrollment); and Type D,
technical universities.
3.2. Knowledge about HPV and HPV Vaccination
Figure 1 shows the proportion of correct responses to knowledge items for vaccinated and
unvaccinated participants. The proportion of correct responses for all the knowledge items was higher
for vaccinated participants than for the unvaccinated participants. Among the items with a low
proportion of correct responses were “there is a cure for HPV infection”, “HPV can cause oral cancer”
and “most people with HPV do not experience any symptoms”. The mean total knowledge score of the
vaccinated participants was 13.1 (SD ± 4.6) and it was significantly higher (t(4218) = 6.575, p < 0.001,
and Cohen’s d = 0.33) than the mean total knowledge score of the participants who had not received
the HPV vaccine (11.5 ± 5.1).
3.3. Health Beliefs Regarding HPV and the HPV Vaccination
Figure 2 shows the proportion of agreement with HBM-derived items for vaccinated and
unvaccinated participants. For items in the domains of susceptibility and perceived benefit, participants
who received the HPV vaccination had a higher proportion of agreement than those who had not
received the vaccination. However, there was a slightly higher agreement among the unvaccinated
participants in two of the three perceived severity items. For perceived barriers to HPV vaccination,
participants who had not received the vaccination reported a higher agreement for the item, “fear of
side effects of HPV vaccination”.
3.4. HPV Vaccination Uptake
A total of 463 participants (11.0%, 95% confidence interval (CI) 10.1 to 11.9) reported that they had
been vaccinated against HPV, and 3757 participants (89.0%, 95% CI 88.1 to 89.9) reported that they did
not have the vaccination. Univariate analyses indicated that HPV vaccine uptake was associated with
older age, being in a higher year of study, place of birth in a city area, residing in eastern China, higher
maternal and paternal education levels, a higher monthly disposable fund, perceived family economic
status being rich or intermediate, having ever had sexual experience, a higher total knowledge score,
a higher perception of susceptibility, and perceived effectiveness of the HPV vaccine (Table 1).
Figure 3 shows the factors affecting HPV vaccine uptake analyzed using PLS-SEM. The model
showed that older age (β = 0.084 and p = 0.006), being born in a city area (β = 0.058 and p = 0.002),
residing in eastern China (β = 0.033 and p = 0.024), a higher monthly disposable fund, a higher total
knowledge score (β = 0.062 and p < 0.001), and a higher perceived susceptibility (β = 0.043 and
p = 0.002) had a positive and significant direct association with HPV vaccine uptake. The adjusted R2
for vaccination status in this model was 0.04, which indicates that 4% of HPV vaccination uptake could
be explained by this model.
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3.5. Willingness to Receive the HPV Vaccination
Among the 3757 participants who had not received the HPV vaccination, 53.5% (n = 2010)
responded “yes” and 46.5% (n = 1747) answered “no” to willingness to receive the HPV vaccine.
As shown in Table 2, there were significant associations between most of the variables investigated and
willingness to receive the HPV vaccine in the univariate analyses (Table 2).
Table 2. Univariate analyses of factors associated with intention to take HPV vaccination (N = 3757).
Frequency (%) Univariate
Intention to Take HPV Vaccination
Yes (n = 2010) No (n = 1747) p-Value
Demographic Characteristics
Age group (years old)
16–18 539 (14.3) 269 (49.9) 270 (50.1)
19–22 2764 (73.6) 1444 (52.2) 1320 (47.8) p < 0.001
23 and above 454 (12.1) 297 (65.4) 157 (34.6)
Ethnicity
Han 3329 (88.6) 1773 (53.3) 1556 (46.7) 0.440
Others 428 (11.4) 237 (55.4) 191 (44.6)
Birthplace
Village 2488 (66.2) 1231 (49.5) 1257 (50.5)
Town 679 (18.1) 411 (60.5) 268 (39.5) p < 0.001
City 590 (15.7) 368 (62.4) 222 (37.6)
Location of school
East China 1400 (37.3) 796 (56.9) 604 (43.1)
West China 1573 (41.9) 852 (54.2) 721 (45.8) p < 0.001
Central China 784 (20.9) 362 (46.2) 422 (53.8)
Type of university
Level A 2024 (53.9) 1148 (56.7) 876 (43.3)
Level B 1142 (30.4) 572 (50.1) 570 (49.9) p < 0.001
Level C 282 (7.5) 136 (48.2) 146 (51.8)
Technical level 309 (8.2) 154 (49.8) 155 (50.2)
Year of study
First-year 1765 (47.0) 876 (49.6) 889 (50.4)
Second-year 774 (20.6) 374 (48.3) 400 (51.7)
Third-year 545 (14.5) 303 (55.6) 242 (44.4) p < 0.001
Fourth-year 370 (9.8) 239 (64.6) 131 (35.4)
Fifth-year and postgraduate 303 (8.1) 218 (71.9) 85 (28.1)
Study program
Medical related major 2632 (70.1) 1142 (54.8) 1190 (45.2) 0.017
Non-medical related major 1125 (29.9) 568 (50.5) 557 (49.5)
Maternal educational level
Elementary school and below 1239 (34.4) 612 (47.3) 681 (52.7)
Junior high school 1356 (36.1) 715 (52.7) 641 (47.3) p < 0.001
High school or secondary school 757 (20.1) 463 (61.2) 294 (38.8)
University and above 351 (9.3) 220 (62.7) 131 (37.3)
Paternal educational level
Elementary school and below 743 (19.8) 352 (47.4) 391 (52.6)
Junior high school 1565 (41.7) 788 (50.4) 777 (49.6) p < 0.001
High school or secondary school 1002 (26.7) 583 (58.2) 419 (41.8)
University and above 447 (11.9) 287 (64.2) 160 (35.8)
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Table 2. Cont.
Frequency (%) Univariate
Intention to Take HPV Vaccination
Yes (n = 2010) No (n = 1747) p-Value
Monthly disposable fund (RMB)
<1000 1108 (29.5) 526 (47.5) 582 (52.5)
1000–1999 2096 (55.8) 1116 (53.2) 980 (46.8) p < 0.001
2000 and above 553 (14.7) 368 (66.5) 185 (33.5)
Perceived family economic status
Rich/Intermediate 2193 (58.4) 1250 (57.0) 943 (43.0) p < 0.001
Poor 1564 (41.6) 760 (48.6) 804 (51.4)
Sexual risk profile
Ever had sexual experience
Yes 642 (17.1) 397 (61.8) 245 (38.2) p < 0.001
No 3115 (82.9) 1613 (51.8) 1502 (48.2)
HPV knowledge
Knowledge score 0-12 1861 (49.5) 855 (45.9) 1006 (54.1) p < 0.001
Knowledge score 13-20 1896 (50.5) 1155 (60.9) 741 (39.1)
Attitudes
Perceived susceptibility
Women in general have a high risk of contracting
HPV in their lifetime
Yes 2801 (74.6) 1611 (57.5) 1190 (42.5) p < 0.001
No 956 (25.4) 399 (41.7) 557 (58.3)
Women in general have a high risk of having genital
warts in their lifetime
Yes 2074 (55.2) 1155 (55.7) 919 (44.3) 0.003
No 1683 (44.8) 855 (50.8) 828 (49.2)
Women in general have a high risk of having
cervical/vulvar cancer in their lifetime
Yes 2661 (70.8) 1481 (55.7) 1180 (44.3) p < 0.001
No 1096 (29.2) 529 (48.3) 567 (51.7)
Perceived severity
Harms of HPV infection for women are severe
Yes 3325 (88.5) 1799 (54.1) 1526 (45.9) 0.040
No 432 (11.5) 211 (48.8) 221 (51.2)
Harms of genital warts for women are severe
Yes 3224 (85.8) 1733 (53.8) 1491 (46.2) 0.454
No 533 (14.2) 277 (52.0) 256 (48.0)
Harms of cervical/vulvar cancer for women are
severe
Yes 3489 (92.9) 1893 (54.3) 1596 (45.7) 0.001
No 268 (7.1) 117 (43.7) 151 (56.3)
Perceived benefit
HPV vaccines are highly effective in preventing me
from HPV infection
Yes 3327 (88.6) 1850 (55.6) 1477 (44.4) p < 0.001
No 430 (11.4) 160 (37.2) 270 (62.8)
HPV vaccines are highly effective in preventing me
from genital warts
Yes 2789 (74.2) 1542 (55.3) 1247 (44.7) p < 0.001
No 968 (25.8) 468 (48.3) 500 (51.7)
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Table 2. Cont.
Frequency (%) Univariate
Intention to Take HPV Vaccination
Yes (n = 2010) No (n = 1747) p-Value
HPV vaccines are highly effective in preventing me
from cervical/vulvar cancer
Yes 3122 (83.1) 1754 (56.2) 1368 (43.8) p < 0.001
No 635 (16.9) 256 (40.3) 379 (59.7)
Perceived barriers
High cost of HPV vaccination
Yes 394 (10.5) 179 (45.4) 215 (54.6) 0.001
No 3363 (89.5) 1831 (54.4) 1532 (45.6)
Fear of severe side effects after receiving
HPV vaccination
Yes 987 (26.3) 474 (48.0) 513 (52.0) p < 0.001
No 2770 (73.7) 1536 (55.5) 1234 (44.5)
Types of University: Type A, National key universities and provincial key colleges; Type B, general undergraduate
universities (national enrollment); Type C, local undergraduate universities (provincial enrollment); and Type D,
technical universities.
Figure 4 shows the factors affecting willingness to receive the HPV vaccination studied using
PLS-SEM. The model showed that demographic characteristics, namely a higher family economic status
(β = 0.03 and p = 0.039), a higher monthly disposable fund (β = 0.045 and p = 0.007), higher maternal
education (β = 0.038 and p = 0.004), attending a large scale university (β = 0.037 and p = 0.012), and
a higher year of study (β = 0.094 and p < 0.001) had significant direct associations with willingness
to receive the HPV vaccine. Total knowledge score had the highest beta coefficient (β = 0.138 and
p < 0.001), indicating significant relevance of knowledge in predicting willingness to receive the
HPV vaccination. For the HBM construct, both perceived susceptibility (β = 0.092 and p < 0.001)
and perceived benefit (β = 0.088 and p < 0.001) had positive and significant direct associations with
willingness to receive the HPV vaccine, while perceived barriers (β = −0.071 and p < 0.001) had a
negative association with willingness to receive the HPV vaccine. Having had sexual experience
(β = 0.041 and p < 0.007) had a positive significant association with willingness to receive the HPV
vaccine. The adjusted R2 was 0.094, indicating that 9.4% of willingness to receive the HPV vaccination
could be explained by this model.
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4. Discussion
This study provides the first evidence of female college students’ HPV vaccine uptake rate in
mainland China. Nearly three years after the introduction of the HPV vaccines in China, the uptake
rate of 11.0% (95% CI 10.1 to 11.9) among the surveyed participants implies the need to enhance HPV
vaccine uptake among young women in China. Nevertheless, the rate is slightly higher than reported
among young women in Hong Kong (9.7%), in 2008, when the vaccines were newly introduced to
the country [23]. The HPV vaccine uptake rate has remained low in other countries in Asia, such as
Singapore where only 13.6% women aged 18 to 26 years reported having been immunized against
HPV [24]. In this study, based on the results of the PLS-SEM, indicators of higher socioeconomic status
such as residing in the eastern region, being born in a city area, and a higher monthly disposable fund
were found to correlate with the HPV vaccine uptake. This finding implies that socioeconomic status
has an important role in influencing HPV vaccine uptake among female college students. There are
gradually decreasing vaccination rates from eastern to western China corresponding to the decrease in
socioeconomic status from the eastern to the western region. These regional differences in HPV vaccine
uptake rates warrant considerable attention. A recent study showed that rural residents had higher
incidence rates of cervical cancer than urban residents. Higher incidence rates occurred in central
China, followed by western, and then eastern China [25]. It is important to note that although there are
higher incidence rates of cervical cancer in central and western China, the HPV vaccine uptake in this
study was lower among participants in the central and western regions. The HPV vaccination rates
varied geographically according to the level of socioeconomic status found in this study, a finding
consistent with that from Western countries [26,27]. This demonstrates the importance of scaling up
HPV vaccination coverage in central and western regions, where the highest incidence rates of cervical
cancer and lower rates of HPV vaccine uptake were evident.
This study also observed a greater likelihood of HPV vaccination among older than among
younger female college students. This highlights the need to promote HPV vaccination among younger
age college students by informing them of the importance of early protection against HPV infections.
It is important to inform them of recent evidence indicating that young women in China aged 25 and
below presented the highest HPV infection rate [15]. They should also be aware that protection against
HPV infections by vaccination is extremely important because mounting evidence shows that sexual
intercourse among young undergraduate students in China is prevalent [28,29] and that consistent
condom use is reported by only slightly over half of the students with sexual experience [29].
Another important highlight of the finding was the lower proportion of correct responses for
all knowledge items among those who had not taken the vaccine as compared with those who had
received the HPV vaccination. The PLS-SEM also revealed a strong influence of knowledge on HPV
vaccine uptake. This indicates that increasing knowledge or awareness is an important factor in raising
HPV vaccination rates. Perceived susceptibility was found to have a positive association with HPV
vaccine uptake, which has likewise been found in many other studies on young adults in Asia and
in Western countries [25,30–32]. This highlights the importance of psychosocial predictors of HPV
vaccine uptake in China. One possible tactic for raising the perception of susceptibility among young
people is to raise their awareness of the high degree of infectiousness of HPV in China. It is of the
utmost importance to inform young college women about recent data showing the high prevalence of
HPV among women in China [13,14], and most importantly that young women are the group with the
highest HPV infection rate [15].
The proportion of nearly 54% female college students willing to receive HPV vaccination in
this study is similar to that found in a recent smaller-scale study conducted among young women
in China [33]. The model of willingness to receive HPV vaccination is important to informing
strategies that emphasize a socioeconomic-based approach targeting lower-income groups and rural
residents. Given the evidence of low willingness to receive the HPV vaccination and high cervical
cancer burden among the lower socioeconomic group [25], immediate strategies aimed at increasing
HPV vaccine uptake among young women from lower socioeconomic groups in China are highly
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warranted. Various strategies have been suggested, and one example is the proposed “semi-mandatory
HPV vaccination strategy,” which subsidizes HPV vaccination targeted at low-income settings for
high-risk individuals [34]. Subsidizing the underserved population is highly recommended as a
cost-effectiveness analysis evaluating the public financing of HPV vaccination found that women from
lower-income quintiles gained greater financial risk protection as compared with those in the upper
wealth quintiles [35]. Furthermore, regional disparities in willingness to receive the HPV vaccination
found in this study demand targeted approaches to enhance the willingness to be vaccinated against
HPV in high-risk geographic areas, particularly in the central and western regions of China.
The model also revealed that among all factors investigated, knowledge was identified as a
strong driver of willingness to be vaccinated against HPV infection. A recent publication revealed
that school-based education was effective and appropriate for increasing HPV-related knowledge and
acceptability of HPV vaccines among junior middle school students in China [36]. Campus-based
health education on HPV infection and cervical cancer prevention should, thus, be introduced to
enrich and increase the level of knowledge and subsequent HPV vaccine coverage rate among female
college students.
Our study suggests that imparting perceived susceptibility and perceived benefits could increase
students’ willingness to take the HPV vaccine. Having a good understanding of the potential benefits
of the HPV vaccination could outweigh perceived barriers to receiving the HPV vaccination [30].
Information regarding the benefits of the HPV vaccination should be emphasized among young people.
This includes information about the prevention of HPV infection and cervical cancers as well as the
reduction of the occurrence of genital warts and anal and penile cancers [32].
Our model indicated that students who have had sexual experience are more likely to express
a willingness to receive the HPV vaccination. Further studies need to be conducted to find reasons
for unwillingness to be vaccinated against HPV. These could include a perceived lack of risk due to
not having had sexual intercourse or social stigma associated with seeking HPV vaccines, as found in
other studies [37,38]. The results indicate the need to highlight the importance of HPV vaccination
among female college students who have never had a sexual experience. They should be made aware
that HPV vaccination is most effective when administered before exposure to any HPV infection [39].
Limitations
This study is not without limitations. The main limitations are the nature of the cross-sectional
study, which was unable to provide inferential causality, and the use of self-reported data, which
can be subject to self-reporting bias. Of note, the HPV vaccine uptake rate found by this study
may not be nationally representative, and therefore warrants cautious interpretation. The results
should be interpreted with caution. Despite these limitations, the sample was large with diverse
sociodemographic backgrounds representative of female college students from the eastern, central,
and western regions of China.
5. Conclusions
This study found that HPV vaccination rates remain critically low among female college students
approximately three years after the licensure of the HPV vaccines in China. Despite the low vaccination
rate, the overall acceptability of the vaccine among the unvaccinated was moderate. Most importantly,
the study found associations between geographical region, socioeconomic status, and young college
women’s knowledge and beliefs about both HPV vaccine uptake and willingness to receive the HPV
vaccine. The findings suggest that it is essential to establish a campus-based HPV immunization
delivery program.
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